Edgar Filing: IDERA PHARMACEUTICALS, INC.

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â BAKER JULIAN

2. Date of Event Requiring Statement (Month/Day/Year)
03/10/2014

3. Issuer Name and Ticker or Trading Symbol
IDERA PHARMACEUTICALS, INC. [IDP]

(Last)

(First)

(Middle)

667 MADISON AVENUE, 21ST FLOOR

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

NEW YORK,Â NYÂ US 10065

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	171,548	I	See Footnotes ⁽¹⁾ ⁽⁴⁾
Common Stock	1,406,423	I	See Footnotes ⁽²⁾ ⁽⁴⁾
Common Stock	35,105	I	See Footnotes ⁽³⁾ ⁽⁴⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2018	Common Stock	2,250,846	$ 0.47	I	See Footnotes ⁽¹⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2018	Common Stock	17,626,445	$ 0.47	I	See Footnotes ⁽²⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2018	Common Stock	439,036	$ 0.47	I	See Footnotes ⁽³⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2020	Common Stock	1,752,291	$ 0.01	I	See Footnotes ⁽¹⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2020	Common Stock	13,722,245	$ 0.01	I	See Footnotes ⁽²⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2020	Common Stock	341,791	$ 0.01	I	See Footnotes ⁽³⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	09/25/2013	09/25/2020	Common Stock	465,230	$ 0.01	I	See Footnotes ⁽¹⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	09/25/2013	09/25/2020	Common Stock	3,620,051	$ 0.01	I	See Footnotes ⁽²⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	09/25/2013	09/25/2020	Common Stock	90,694	$ 0.01	I	See Footnotes ⁽³⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	02/05/2014	02/10/2021	Common Stock	172,406	$ 0.01	I	See Footnotes ⁽¹⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	02/05/2014	02/10/2021	Common Stock	1,938,274	$ 0.01	I	See Footnotes ⁽²⁾ ⁽⁴⁾
Common Stock Warrant ( right to buy)	02/05/2014	02/10/2021	Common Stock	48,070	$ 0.01	I	See Footnotes ⁽³⁾ ⁽⁴⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
BAKER JULIAN 667 MADISON AVENUE, 21ST FLOOR NEW YORK,Â NYÂ US 10065	Â X	Â	Â	Â
BAKER BROS. ADVISORS LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK,Â NYÂ US 10065	Â X	Â	Â	Â
BAKER FELIX 667 MADISON AVENUE, 21ST FLOOR NEW YORK,Â NYÂ US 10065	Â X	Â	Â	Â
Baker Bros. Advisors (GP) LLC 667 MADISION AVENUE 21ST FLOOR NEW YORK,Â NYÂ US 10065	Â X	Â	Â	Â
667, L.P. 667 MADISON AVENUE 21ST FLOOR NEW YORK,Â NYÂ US 10065	Â X	Â	Â	Â
14159, L.P. 667 MADISION AVENUE, 21ST FLOOR NEW YORK,Â NYÂ US 10065	Â X	Â	Â	Â
Baker Brothers Life Sciences LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK,Â NYÂ US 10065	Â X	Â	Â	Â

Signatures

/s/ Julian C. Baker		03/12/2014
^**Signature of Reporting Person		Date
BAKER BROS. ADVISORS LP Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing		03/12/2014
^**Signature of Reporting Person		Date
/s/ Felix J. Baker		03/12/2014
^**Signature of Reporting Person		Date
BAKER BROS. ADVISORS (GP) LLC Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing		03/12/2014
^**Signature of Reporting Person		Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing		03/12/2014
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock of Idera Pharmaceuticals Inc. (the "Issuer") reported in Table I and Warrants reported in Table II directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
(2)	As result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Table I and Warrants reported in Table II directly held by Baker Brothers Life Sciences, L.P. ("Life Sciences") a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
(3)	As result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Table I and Warrants reported in Table II directly held by 14159, L.P. ("14159") a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.
(4)	Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Â Remarks: JulianÂ C.Â BakerÂ andÂ Dr.Â KelvinÂ Neu,Â respectivelyÂ aÂ principalÂ andÂ anÂ employeeÂ ofÂ theÂ BakerÂ Bros.Â AdvisorsÂ LPÂ (theÂ "Adviser")Â areÂ directorsÂ ofÂ IderaÂ PharmaceuticalsÂ (theÂ "Issuer").Â ForÂ purposesÂ ofÂ SectionÂ 16Â ofÂ theÂ SecuritiesÂ ExchangeÂ ActÂ ofÂ 1934,Â asÂ amendedÂ theÂ ReportingÂ PersonsÂ areÂ deemedÂ directorsÂ byÂ deputizationÂ byÂ virtueÂ ofÂ theirÂ representationÂ onÂ theÂ BoardÂ ofÂ theÂ Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.